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Upper Airway Stimulation for 
Treatment of OSA 
Maurits Boon, MD 
Co-Director Jefferson Voice and Swallowing Center 
Department of Otolaryngology – Head and Neck Surgery 
Introduction: 
• What is OSA 
• Consequences of untreated OSA 
• CPAP therapy 
• Why do we need alternatives to 
positive airway pressure (PAP) 
therapy 
• How do we evaluate a patient for 
alternative treatments 
• Who is a candidate 
• What are the alternatives 
Obstructive Sleep Apnea 
How we Measure OSA 
• Hypopnea: 
• Reduction in airflow of 30% for 10 seconds with corresponding 
desaturation of 4% 
• Apnea: 
• Cessation of breathing for 10 seconds 
• RERA: 
• Respiratory event related arousal 
• Apnea Hypopnea Index (AHI) 
•  Average of apneas and hypopneas per hour 
• Respiratory Disturbance Index (RDI) 
• Apneas, hypopneas and RERA on average per hour 
Scoring Sleep Studies 
 
 
• <5 Normal 
• >5-15 Mild 
• >15-30 Moderate 
• >30 Severe 
What are the consequences of untreated  
OSA? 
• Cardiovascular 
• Hypertension 
• Heart failure 
• MI 
• Arrhythmia 
• Stroke 
• Pulmonary 
• Endocrine 
• Diabetes 
• Other 
• Reflux 
• Functional  
Treatment 
• Surgical treatments predate medical treatments 
• Tracheotomy 
• UPPP 
• CPAP shortly thereafter 
Positive Airway Pressure 
CPAP = continuous positive airway pressure. 
CPAP-Treated Airway OSA 
Benefits of CPAP 
• Sleep quality 
• Reduced snoring 
• Alertness 
• Reduced GERD 
• Depressive symptoms 
• Blood pressure control 
• Heart function, esp atrial fibrillation 
• Mortality rate 
Kanathur et al.  Therapy in Sleep Medicine, 2012 
Adverse Effects of CPAP 
Hoffstein V, Viner S, 
Mateika S, et al. Am 
Rev Respir Dis 
1992;145(4 Pt 1):841-
45. 
Waldhorn RE, Herrick 
TW, Nguyen MC, et al. 
Chest 1990;97(1):33-
38.  
Nino-Murcia G, Mc 
Cann CC, Bliwise DL, 
et al. West J Med 
1989;150(2):165-69. 
Why do we need alternatives? 
• Patients who cannot tolerate CPAP 
• Non-adherence 46-83% 
• Better response with more severe 
symptoms 
Weaver, TE  et al.  Adherence to Continuous Positive Airway Pressure 
Therapy:  The Challenge to effective treatment.  Proceedings of the 
American Thoaracic Society.  5(2).  Feb  173-8 
Expiratory Positive Airway 
Pressure (EPAP) 
• Theravent® 
• Provent® 
• Imposes expiratory 
resistance 
• Stent open airways 
• 94% compliance  
Rosenthal, L. et al. A.  JCSM 5(^) 
2009 
Provent® 
• Well tolerated 
• Decrease in AHI by 42.7% (vs 
10% sham) 
• Further research is required to 
identify the ideal candidates.  
 
1. Berry, B. et al.  A novel nasal expiratory positive airway pressure device 
For the treatment of OSA:  A randomized controlled trial.  Sleep 2011 34(4)479-85 
2. Rosenthal, L. et al. A Multicenter, Prospective Study of a Novel Nasal EPAP  
Device in the Treatment of Obstructive 
Sleep Apnea:  Efficacy and 30-Day Adherenence.  JCSM 5(^) 2009 
 
Oral Appliances: 
• Useful in primary snoring and 
OSA 
• 2 Types: 
• Tongue retaining 
• Mandibular advancing 
 
Oral Appliances: 
• Success in treatment 
• Mild to moderate OSA 
• AHI <10 in 52% 
• Treatment adherence 76% 
• Adverse events: 
• Tooth movement 
• Changes in occlusion 
• TMJ pain 
• Salivation 
• Gum irritation 
• Tongue pain (tongue retaining 
devices only) 
Ferguson, et al, Oral appliances for snoring and obstructive sleep 
Apnea:  A review.  Sleep 29(2):244-62  2006 
Body Positioning Devices 
What is sleep surgery? 
• Surgery to facilitate other modalities of treatment 
• Improve tolerance of CPAP 
• Improve use of oral appliances or EPAP 
• Surgery to definitively treat OSA 
• Bariatric surgery 
• Modification of the upper airway 
• Upper airway stimulation (Inspire®) 
Who is a candidate? 
• Diagnosed OSA by appropriate 
PSG screening 
• BMI (<40) 
• Willing to undergo postoperative 
PSG to objectively assess 
outcome of alternative 
treatment 
Mueller’s Maneuver 
Evaluation: Fujita Classification 
Retropalatal Combined Retrolingual 
Sleep Endoscopy 
• Flexible fiberoptic examination of patient 
with sedation 
• Assesses airway under more “true” to 
sleep circumstances 
• ?Better assessment of site of obstruction 


Surgical Management:   
 
• Addressing different sites of obstruction 
• Nose 
• Palate 
• Tongue base / Hypopharyngeal  
Surgical Management 
Nasal Obstruction Surgery 
• <20%successful in mild 
OSAS with nasal obstruction 
• Facilitate CPAP compliance 
• Decreased CPAP 
pressures  
• Tolerance of different 
masks 
 
Poirier J. Et al.  The effect of of nasal surgery on nasal continuous 
Postive airway pressure compliance.  Laryngoscope.  2013 epub ahead of print  
Palatal Procedures 
• Laser assisted Uvuloplasty 
• Injection snoreplasty 
• Cautery Assisted Palatal 
Stiffening Operation 
(CAPSO) 
• Tonsillectomy 
• Pillar implants 
• UvuloPalatoPharyngoPlasty 
(UPPP) 
 
• Anterior Palatoplasty 
• ZP3 
• Expansion 
sphincteroplasty 
• Palatal advancement 
• Lateral pharyngoplasty 
 
Management:  Tongue Base 
• Radiofrequency 
reduction 
• Laser midline 
glossectomy  
• Laser Lingualplasty 
• Lingual tonsillectomy 
• SMILE procedure 
• TORS 
 
• Hyoid Myotomy and 
advancement +/-Tongue base 
suspension 
• Genioglossus advancement 
• Hypoglossal Nerve Stimulator  
Bimaxillary Advancement 
• Osteotomies of maxilla and mandible 
• Addresses oropharyngeal and 
hypopharyngeal airway 
• Can be used after failed “phase 1” 
sleep surgery 
• 90-95% success 
• Limited by patient acceptance  
Tracheotomy 
• “Gold Standard” 
• Temporary adjunct to 
procedures in severe 
cases 
 
Upper Airway Stimulation: 
• Surgically implanted 
device  
• Does not alter native 
anatomy of pharynx 
and tongue base 
How Does Inspire Therapy Work? 
• Inspire therapy: 
• Is fully implanted 
• Senses breathing 
• Delivers mild stimulation to key 
airway muscles 
• Turns on and off with a handheld 
remote 
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Inspire System 
33 
Patient Sleep 
Remote Physician 
Programmer 
Stimulation Lead 
Respiratory 
Sensing Lead 
Implantable Pulse Generator 
Adjustability of Device 
• Implantable neurostimulation systems are 
adjustable to optimize therapy 
• Inspire is a closed-loop system measuring 
respiration and providing stimulaton 
• Titration occurs during an in-lab sleep study 
34 
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Upper Airway Stimulation Effect 
 Stimulation Active No Stimulation 
EEG 
EMG 
Nasal 
Therm 
Chest 
Abdm 
SaO2 
35 
Inspire Therapy affects the airway at  
multiple-levels 
Tx OFF - Palate Tx ON - Palate 
OFF – Tongue Base ON – Tongue Base 
STAR Trial Results 
37 
N Engl J Med 2014;370:139-49; p 143-4; Figure 3, p 147. 
Green underlines added for clarity in text excerpts. 
Star Trial:   Stimulation for Treatment of Apnea Reduction 
Significant Reduction In OSA Severity 
Significant Improvement In Daytime Functioning 
Reduction in Snoring 
40 
Source: Inspire STAR pivotal trial 
Inspire Therapy Visits 
Routine 
Follow-ups 
Sleep profile  
 
Anatomy check 
Typically 
outpatient 
Assessment Implant Follow Up 
Therapy 
activation 
 
Therapy 
optimization 
 
Routine annual 
follow up 
Who is a candidate for Upper Airway Stimulation 
• Moderate to severe OSA with AHI 20 or more 
• BMI 32 or less 
• No significant central component of apneas 
• Appropriate anatomy based on sleep endoscopy 


Inspire Therapy Visits 
Routine 
Follow-ups 
Sleep profile  
 
Anatomy check 
Typically 
outpatient 
Assessment Implant Follow Up 
Therapy 
activation 
 
Therapy 
optimization 
 
Routine annual 
follow up 
Surgery: 
47 
Hyoglossus 
 
Hypoglossal Nerve (XII) 
 
Mylohyoid 
 
48 
Plunge Point in fresh cadaver 
GGh & GGo ramifying 
49 
Medtronic Xomed NIM 3.0 
50 
NIM EMG Electrode Placement 
51 
wikimedia.org 
NIM Set up 
EMG Monitoring Electrodes:  
•  Genioglossus: insert towards mid-inferior 
section of the tongue along inner molars,  
underneath the tongue using Prass Paired 
Electrodes (18 or 12.5 mm) 
Goal: Include m-XII branches for optimal 
protrusor identification/recruitment 
 
•  Stylo-/Hyoglossus: insert along 
ventrolateral aspect, shallow parallel course 
just beneath the mucosa using Prass Paired 
Electrodes (12.5 or 18 mm) 
Goal: Exclude l-XII branches for optimal 
retractor identification/exclusion 
 
Stimulation: 0.3 – 0.8 mA 
Identify final retractor branch, evaluate 
challenging branches for inclusion 
Goal: Exclude l-XII branches for optimal 
retractor identification/exclusion 
Goal: Include m-XII branches for optimal 
protrusor identification/recruitment 


Respiratory Sensing Lead 
Sensing (Sense) Lead 
Location 
• Inferior to 5th rib, and  
Superior to 6th rib 
• 5 cm interfascial tunnel;  
deep to external, superficial to 
internal, intercostal muscle 
• Anchor to fascia/muscle 
Functions  
• Obtain breathing pressures via 
sensor membrane 
• Convert pressure changes to 
electrical current waveform 
• Deliver waveform to IPG for 
closed-loop therapy 



58 
Lateral view, showing stim cuff electrode 
include vertebrae and chin 
AP view, showing IPG/lead wrap and sensing lead 
include IPG and sensor lead 
Inspire Therapy Visits 
Routine 
Follow-ups 
Sleep profile  
 
Anatomy check 
Typically 
outpatient 
Assessment Implant Follow Up 
Therapy 
activation 
 
Therapy 
optimization 
 
Routine annual 
follow up 
Experience To Date 
• 14 implants 
• 8 post implant titrattions 
• First adult Down’s syndrome patient implanted in country 
• 1 of 10 centers in the post commercial trial 
Results 
 
 
   AHI Pre   AHI Post 
 
• Patient 1:       27.2   1 
• Patient 2:  23.0   7.7 
• Patient 3:   18.4   5.1 
• Patient 4:  25   5.7 
• Patient 5:  44   5.1 
• Patient 6:  26.3   0 
• Patient 7:  86.3   7.7 
• Patient 8:  50.1   15* 
* = Down’s patient with 8 central apneas  
• I have but one misgiving. I believe that my 
characterization of the first generation of this device as a 
“Model T” was misleading. This really is a Lamborghini, 
and I am really happy to have one driving my breathing 
every night. It is making a big difference in my life. In 
fact, I just now realized as I’m writing this that I have had 
enough energy in the evening that I’m taking a yoga class 
that starts at 8 p.m.  On January 29, 2015 that would 
have been impossible because I would have been wiped 
out before 5:30 p.m.  What a gift. 
Conclusions 
• OSA is a prevalent disease 
• Impacts the health of all of 
our patients 
• CPAP remains first line 
therapy  
• Compliance remains an issue 
• Multiple non-PAP therapy 
options exist and are 
evolving 
• EPAP 
• Oral appliances 
• Surgery 
• Upper airway stimulation 
represents one of the most 
promising therapies for a 
select group of patients 
